Rhythm Pharmaceuticals Q2 EPS $(0.82) Misses $(0.81) Estimate, Sales $19.22M Beat $14.79M Estimate
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals reported Q2 losses of $(0.82) per share, missing the analyst consensus estimate of $(0.81) by 1.23%. However, the company's quarterly sales of $19.22 million beat the analyst consensus estimate of $14.79 million by 29.95%, marking a 731.31% increase from the same period last year.
August 01, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rhythm Pharmaceuticals' Q2 earnings per share missed estimates, but sales significantly exceeded expectations.
While Rhythm Pharmaceuticals missed EPS estimates, the significant beat on sales could offset the negative impact. The market reaction could be mixed, hence a neutral score is given.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100